Central Bank & Trust Co. Trims Holdings in Pfizer Inc. (NYSE:PFE)

Central Bank & Trust Co. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 12.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,321 shares of the biopharmaceutical company’s stock after selling 2,517 shares during the quarter. Central Bank & Trust Co.’s holdings in Pfizer were worth $484,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of PFE. Clifford Swan Investment Counsel LLC grew its stake in shares of Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after buying an additional 18,611 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Pfizer during the fourth quarter valued at $16,166,000. First Heartland Consultants Inc. raised its position in shares of Pfizer by 43.3% in the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 3,933 shares during the last quarter. ORG Partners LLC boosted its stake in Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Finally, Kempner Capital Management Inc. bought a new stake in Pfizer during the 1st quarter valued at about $2,439,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.45 during midday trading on Monday, hitting $28.75. 10,439,585 shares of the company’s stock traded hands, compared to its average volume of 39,386,074. The firm has a fifty day moving average of $28.75 and a 200 day moving average of $27.91. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.19. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market capitalization of $162.91 billion, a price-to-earnings ratio of -479.17, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business posted $0.67 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.84%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, July 31st. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.